Dr. med. Dirk Manski

 You are here: Urology Textbook > Drugs in Urology > Alpha-blocker > Silodosin

Alpha-blocker (5/6): Silodosin

Review Literatur: (Chapple, 2004).

General Pharmacology of Silodosin

Mechanism of Action of Silodosin

Silodosin is a new selective alpha1A-blocker with a favourable cardiovascular side effect rate (Cantrell et al, 2010). Alpha-blocker are used for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Please see section general pharmacology of alpha-blocker.

Pharmacokinetics of Silodosin

Bioavailability 32%, high plasma protein binding, hepatic metabolization, elimination half life 13 h, biliary and renal excretion of metabolites.

General Side Effects of Alpha-Blocker

Contraindications of Alpha-Blocker

Urological Contraindications:

Conservative treatment of BPH is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.

Cardiac Contraindications:

Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.

Other contraindications:

Silodosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.

Specific Contraindications of Silodosin

Dosage of Silodosin

8 mg 1-0-0. Reduce dosage to 4 mg in patients with renal insufficiency (<50 ml/min).

Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Cantrell, M. A.; Bream-Rouwenhorst, H. R.; Hemerson, P. & Magera, J. S.
Silodosin for benign prostatic hyperplasia.
Ann Pharmacother, 2010, 44, 302-310.

Chapple 2004 CHAPPLE, C. R.:
Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44

  Deutsche Version: Silodosin